Jan Bednarsch1, Zoltan Czigany1, Isabella Lurje1, Frank Tacke2, Pavel Strnad3, Tom F Ulmer1, Nadine T Gaisa4, Philipp Bruners5, Ulf P Neumann6, Georg Lurje7. 1. Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany. 2. Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany; Department of Hepatology and Gastroenterology, Charité University Medical Center, Berlin, Germany. 3. Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany. 4. Institute of Pathology, University Hospital RWTH Aachen, Aachen, Germany. 5. Department of Radiology, University Hospital RWTH Aachen, Aachen, Germany. 6. Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany; Department of Surgery, Maastricht University Medical Centre (MUMC), Maastricht, The Netherlands. 7. Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen, Germany. Electronic address: glurje@ukaachen.de.
Abstract
BACKGROUND: Major liver resections with portal vein resection (PVR) have emerged as the preferred treatment for patients with perihilar cholangiocarcinoma (pCCA). Whether the resection of the liver should be preferably performed as left- (LH) or right-sided hepatectomy (RH) with or without hilar en-bloc technique is still subject of ongoing debate. METHODS: Between 2011 and 2016, 91 patients with pCCA underwent surgery in curative intent at our institution. Perioperative, pathological and survival data from all consecutive patients undergoing hilar en-bloc resection for pCCA were analyzed retrospectively. Patients undergoing hepatoduodenectomy (n = 8) or ALPPS (Associating liver partition and portal vein ligation for staged hepatectomy) (n = 2) were excluded from the analysis. RESULTS: Tumor grading, microvascular invasion, lymphovascular invasion, N-category, T-category, R-status and UICC-tumor staging were similar in the RH (n = 45) and LH (n = 36) groups. Perioperative morbidity and mortality were higher after RH compared to LH (mortality: 15.6% (7/45) vs. 8.3% (3/36) p = 0.003). Three-year (62% vs. 51%) and the 5-year OS (30% vs. 46%) were comparable between LH and RH groups respectively (p = 0.519, log rank). CONCLUSIONS: The present study supports the concept of surgically aggressive therapy in pCCA. LH and RH hilar en-bloc resection demonstrate a comparable long-term survival, suggesting that LH hilar en-bloc resections are feasible and safe in high-volume centers.
BACKGROUND: Major liver resections with portal vein resection (PVR) have emerged as the preferred treatment for patients with perihilar cholangiocarcinoma (pCCA). Whether the resection of the liver should be preferably performed as left- (LH) or right-sided hepatectomy (RH) with or without hilar en-bloc technique is still subject of ongoing debate. METHODS: Between 2011 and 2016, 91 patients with pCCA underwent surgery in curative intent at our institution. Perioperative, pathological and survival data from all consecutive patients undergoing hilar en-bloc resection for pCCA were analyzed retrospectively. Patients undergoing hepatoduodenectomy (n = 8) or ALPPS (Associating liver partition and portal vein ligation for staged hepatectomy) (n = 2) were excluded from the analysis. RESULTS: Tumor grading, microvascular invasion, lymphovascular invasion, N-category, T-category, R-status and UICC-tumor staging were similar in the RH (n = 45) and LH (n = 36) groups. Perioperative morbidity and mortality were higher after RH compared to LH (mortality: 15.6% (7/45) vs. 8.3% (3/36) p = 0.003). Three-year (62% vs. 51%) and the 5-year OS (30% vs. 46%) were comparable between LH and RH groups respectively (p = 0.519, log rank). CONCLUSIONS: The present study supports the concept of surgically aggressive therapy in pCCA. LH and RH hilar en-bloc resection demonstrate a comparable long-term survival, suggesting that LH hilar en-bloc resections are feasible and safe in high-volume centers.
Authors: Isabella Lurje; Zoltan Czigany; Jan Bednarsch; Nadine Therese Gaisa; Edgar Dahl; Ruth Knüchel; Hannah Miller; Tom Florian Ulmer; Pavel Strnad; Christian Trautwein; Frank Tacke; Ulf Peter Neumann; Georg Lurje Journal: Liver Cancer Date: 2022-01-25 Impact factor: 12.430
Authors: Lynn E Nooijen; Rutger-Jan Swijnenburg; Heinz-Josef Klümpen; Joanne Verheij; Geert Kazemier; Thomas M van Gulik; Joris I Erdmann Journal: Visc Med Date: 2021-01-07
Authors: Lotte C Franken; Pim B Olthof; Joris I Erdmann; Otto M van Delden; Joanne Verheij; Marc G Besselink; Olivier R Busch; Thomas M van Gulik Journal: Hepatobiliary Surg Nutr Date: 2021-04 Impact factor: 8.265
Authors: Jan Bednarsch; Zoltan Czigany; Isabella Lurje; Christian Trautwein; Tom Lüdde; Pavel Strnad; Nadine Therese Gaisa; Alexandra Barabasch; Philipp Bruners; Tom Ulmer; Sven Arke Lang; Ulf Peter Neumann; Georg Lurje Journal: J Gastrointest Surg Date: 2020-06-03 Impact factor: 3.452
Authors: Sandra Pavicevic; Sophie Reichelt; Deniz Uluk; Isabella Lurje; Cornelius Engelmann; Dominik P Modest; Uwe Pelzer; Felix Krenzien; Nathanael Raschzok; Christian Benzing; Igor M Sauer; Sebastian Stintzing; Frank Tacke; Wenzel Schöning; Moritz Schmelzle; Johann Pratschke; Georg Lurje Journal: Cancers (Basel) Date: 2022-02-17 Impact factor: 6.639
Authors: Jan Bednarsch; Zoltan Czigany; Daniel Heise; Sven Arke Lang; Steven W M Olde Damink; Tom Luedde; Philipp Bruners; Tom Florian Ulmer; Ulf Peter Neumann Journal: J Clin Med Date: 2020-05-08 Impact factor: 4.241